Schroder Investment Management Group Purchases 254,212 Shares of Repligen Corporation $RGEN

Schroder Investment Management Group raised its holdings in shares of Repligen Corporation (NASDAQ:RGEN) by 123.2% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 460,609 shares of the biotechnology company’s stock after acquiring an additional 254,212 shares during the quarter. Schroder Investment Management Group owned approximately 0.82% of Repligen worth $61,570,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in RGEN. Brown Capital Management LLC grew its position in shares of Repligen by 16.3% during the second quarter. Brown Capital Management LLC now owns 1,005,276 shares of the biotechnology company’s stock worth $125,036,000 after purchasing an additional 141,241 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in Repligen by 4.1% in the 3rd quarter. Dimensional Fund Advisors LP now owns 799,510 shares of the biotechnology company’s stock worth $106,826,000 after purchasing an additional 31,505 shares during the period. Stephens Investment Management Group LLC grew its holdings in Repligen by 14.4% during the 3rd quarter. Stephens Investment Management Group LLC now owns 598,356 shares of the biotechnology company’s stock valued at $79,982,000 after buying an additional 75,509 shares in the last quarter. Thrivent Financial for Lutherans raised its position in shares of Repligen by 6.7% during the third quarter. Thrivent Financial for Lutherans now owns 458,820 shares of the biotechnology company’s stock valued at $61,331,000 after buying an additional 28,716 shares during the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its holdings in shares of Repligen by 3,219.3% in the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 413,425 shares of the biotechnology company’s stock worth $51,422,000 after buying an additional 400,970 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on RGEN. Wall Street Zen lowered shares of Repligen from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. UBS Group decreased their price target on shares of Repligen from $200.00 to $195.00 and set a “buy” rating on the stock in a research note on Wednesday, February 25th. Barclays cut their price objective on Repligen from $200.00 to $175.00 and set an “overweight” rating for the company in a research report on Wednesday, February 25th. KeyCorp reaffirmed an “overweight” rating on shares of Repligen in a report on Wednesday, February 25th. Finally, Weiss Ratings lowered Repligen from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Tuesday, March 3rd. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $174.58.

Repligen Price Performance

RGEN stock opened at $121.79 on Wednesday. Repligen Corporation has a 52 week low of $102.96 and a 52 week high of $175.77. The firm has a market capitalization of $6.86 billion, a P/E ratio of 143.28, a price-to-earnings-growth ratio of 2.49 and a beta of 1.14. The company has a fifty day simple moving average of $148.33 and a two-hundred day simple moving average of $147.14. The company has a quick ratio of 7.12, a current ratio of 8.37 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last posted its earnings results on Tuesday, February 24th. The biotechnology company reported $0.49 earnings per share for the quarter, topping analysts’ consensus estimates of $0.44 by $0.05. The firm had revenue of $197.91 million for the quarter, compared to the consensus estimate of $192.23 million. Repligen had a net margin of 6.62% and a return on equity of 4.71%. The business’s quarterly revenue was up 18.1% on a year-over-year basis. During the same period in the previous year, the firm posted $0.44 EPS. Repligen has set its FY 2026 guidance at 1.930-2.010 EPS. Analysts anticipate that Repligen Corporation will post 1.72 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Repligen news, Director Karen A. Dawes sold 275 shares of the business’s stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $161.00, for a total transaction of $44,275.00. Following the sale, the director directly owned 91,821 shares of the company’s stock, valued at $14,783,181. The trade was a 0.30% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 1.20% of the stock is owned by insiders.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.